What Alector does

Alector, Inc. is a publicly traded clinical-stage biotechnology company (NASDAQ: ALEC) founded in 2013 and headquartered in South San Francisco, California. The company develops immuno-neurology therapies for neurodegenerative diseases, with a pipeline targeting frontotemporal dementia (FTD), Alzheimer's disease, and Parkinson's disease. Alector combines human genetics, neuroscience, and immunology expertise to develop antibody and siRNA-based therapeutic candidates designed to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Its core technology foundation is the proprietary Alector Brain Carrier (ABC) platform, which uses receptor-mediated transcytosis to deliver therapeutic agents across the blood-brain barrier.

The pipeline included latozinemab (AL001), a progranulin-elevating antibody for FTD-GRN that received FDA Breakthrough Therapy, Fast Track, and Orphan Drug designations; AL101 (nivisnebart), developed with GSK for Alzheimer's disease; and AL002, a TREM2 agonistic antibody developed with AbbVie. The preclinical pipeline leverages ABC technology across multiple modalities including anti-amyloid antibodies, anti-tau siRNA, GCase enzyme replacement, and anti-alpha-synuclein siRNA. Latozinemab received Breakthrough Therapy Designation from the FDA in 2025.

Alector operates as a pre-revenue biotech, generating collaboration revenue rather than product sales through co-development partnerships with GSK ($700 million upfront in 2021) and AbbVie. The company is publicly listed on NASDAQ following its 2019 IPO and subsequent financings including a $75 million public offering in January 2024 and a $50 million debt facility from Hercules Capital in November 2024. The company has suffered multiple clinical trial setbacks in 2025-2026, including the Phase 3 INFRONT-3 failure for latozinemab (October 2025) and the Phase 2 PROGRESS-AD termination for AL101 (April 2026), prompting a 49% workforce reduction and a market capitalization decline to approximately $135 million by December 2025.

Name

Alector

Legal name

Alector, Inc.

Website

https://alector.com

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

101–250 employees

Short description

Alector is a publicly traded clinical-stage biotechnology company developing immuno-neurology antibody therapies and siRNA candidates for neurodegenerative diseases, including frontotemporal dementia, Alzheimer's disease, and Parkinson's disease, using its proprietary ABC blood-brain barrier delivery platform.

Ownership category

akta.pro rank

Product category

Neurodegenerative Disease Therapeutics / Immuno-Neurology Biotechnology

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Enzyme Replacement & Metabolic Disorder Therapies (HLAIAIAB)

Keywords

• Neurodegenerative disease therapeutics
• Immuno-neurology drug development
• Monoclonal antibody pipeline
• Blood-brain barrier delivery
• Clinical-stage biotechnology

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Drug Development and Commercialization: Pre-revenue clinical-stage biotech company. Developing pipeline of therapeutic candidates for neurodegenerative diseases. Revenue will come from product sales upon regulatory approval. Currently no commercial products.
2. Collaborative Development Agreements: Partnership with GSK for co-development and co-commercialization of progranulin franchise programs (AL001 and AL101). Partnership with AbbVie for co-development of AL002. These partnerships provide upfront payments, milestone payments, and potential royalties.
3. Public Equity Offerings: Raised approximately $75 million through public offering of common stock in January 2024 (10.87 million shares). Conducted under shelf registration with SEC.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

Alector is a clinical-stage biotechnology company that discovers and develops biologic therapeutics—including monoclonal antibodies, siRNA candidates, and enzyme replacement therapies—for neurodegenerative diseases such as frontotemporal dementia (FTD-GRN), Alzheimer's disease, Parkinson's disease, and Lewy body dementia. The pipeline is enabled by the proprietary Alector Brain Carrier (ABC) technology, which delivers therapeutic agents across the blood-brain barrier using receptor-mediated transcytosis. The company co-develops and co-commercializes its programs through partnerships with major pharmaceutical companies including GSK and AbbVie.

Product overview

Alector is a clinical-stage biotechnology company developing a pipeline of biologic drug candidates for neurodegenerative diseases. The company's product portfolio centers on immuno-neurology therapeutics targeting genetic pathways involved in neurodegeneration, including progranulin-elevating antibodies (latozinemab/AL001 and AL101), TREM2 agonistic antibodies (AL002), and next-generation candidates leveraging the proprietary Alector Brain Carrier (ABC) technology for enhanced blood-brain barrier delivery. The ABC platform supports multiple modality types including antibodies, siRNAs, and enzyme replacement therapies applied across Alzheimer's disease, frontotemporal dementia, Parkinson's disease, and other neurological conditions. Alector's clinical-stage candidates include latozinemab (AL001) for FTD-GRN and AL101 for Alzheimer's disease (with GSK partnership), while the preclinical pipeline features programs like AL037/AL137-ABC (anti-amyloid beta), AL050-ABC (GCase enzyme replacement), and siRNA-based programs targeting tau, alpha-synuclein, and NLRP3.

Differentiator

Problem solved

Functional benefit

Products and services

• Latozinemab (AL001) Progranulin-elevating monoclonal antibody designed to restore diminished progranulin protein levels to normal ranges in patients with frontotemporal dementia due to GRN gene mutations (FTD-GRN), with the goal of slowing disease progression. Targeted at patients with this rare, rapidly progressing form of dementia.
• AL101 (Nivisnebart / GSK4527226) Progranulin-elevating monoclonal antibody developed in collaboration with GSK for the treatment of early Alzheimer's disease, designed to increase progranulin levels in the brain as a potential strategy for slowing neurodegeneration.
• AL002 TREM2 agonistic antibody for early Alzheimer's disease developed in partnership with AbbVie, targeting neuroinflammation and microglia function to restore immune and nerve cell activity in the brain.
• AL037/AL137-ABC Proprietary anti-amyloid beta (Aβ) antibody paired with the Alector Brain Carrier (ABC) for the treatment of Alzheimer's disease. Designed to remove brain amyloid plaques with potential to reduce ARIA risk and enable subcutaneous delivery.
• AL064/AL164-ABC Anti-tau siRNA combined with the Alector Brain Carrier, targeting tau pathology in Alzheimer's disease and other tauopathies by inhibiting tau mRNA and protein synthesis.
• AL050-ABC Engineered GCase enzyme replacement therapy paired with the Alector Brain Carrier for GBA gene mutation carriers with Parkinson's disease and Lewy body dementia, designed to break down glucocerebroside that accumulates in neurons.
• ADP062-ABC Anti-α-synuclein siRNA combined with the Alector Brain Carrier for Parkinson's disease, targeting α-synuclein pathology by inhibiting mRNA and protein synthesis.
• ADP065-ABC Anti-NLRP3 siRNA combined with the Alector Brain Carrier targeting NLRP3-driven neuroinflammation in Alzheimer's disease and Parkinson's disease.
• Alector Brain Carrier (ABC) technology platform Proprietary blood-brain barrier technology platform using receptor-mediated transcytosis to enhance brain penetration of therapeutic agents, enabling delivery of antibodies, siRNAs, and enzyme replacement therapies to the brain for the treatment of neurodegenerative diseases.

Quantifiable outcome

• Latozinemab increased plasma progranulin levels in FTD-GRN patients (Phase 3 INFRONT-3 trial)
• +5 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core, important and minor.

• GlaxoSmithKline (GSK)coreStrategic or Co-development Partner · 1 January 2021Collaborative agreement with GSK to co-develop and co-commercialize progranulin franchise programs AL001 (latozinemab) and AL101. GSK paid $700 million upfront in 2021. Programs focused on treating frontotemporal dementia (FTD-GRN) and Alzheimer's disease by elevating progranulin levels.
• AbbViecoreStrategic or Co-development Partner · 1 January 2017Partnership formed with AbbVie to co-develop Alector's Alzheimer's-focused lead program AL002. AL002 is a TREM2 agonistic antibody for treatment of early Alzheimer's disease. The partnership leverages AbbVie's global pharmaceutical development and commercialization capabilities.
• AdimabimportantTechnology or Integration · 1 January 2015Strategic alliance with Adimab to access antibody technologies for drug discovery. This partnership provided Alector with access to Adimab's yeast-based antibody discovery platform, supporting the development of antibody therapeutics for neurodegenerative diseases.
• Johnson & Johnson Innovation CenterminorStrategic or Co-development Partner · 1 January 2015Collaborative research agreement with Johnson & Johnson Innovation Center to fund one target through proof-of-concept in disease models. Part of Alector's early strategic partnerships to advance neurodegeneration research.

Scale indicators11 records

Recent moves8 records

Expansion highlights5 records

Market position

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/alector
• Facebookfacebook.com/623768334640916

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds7 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alector